Journals / Selçuk Tıp Dergisi / 2010 / Cilt: 26 - Sayı: 1

Investigation of ADMA, arginine and NO levels of patients with acute attack, stable COPD and cor pulmonale

Akut atak, stabil KOAH ve kor pulmonale hastalarında ADMA, arjinin ve NO düzeylerinin belirlenmesi

Pages
9–13
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

ADMA may therefore represent a novel therapeutic target for the treatment and prevention of pulmonary hypertension and cor pulmonale in COPD patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of our study was to determine serum asymmetric dimethylarginine (ADMA), nitric oxide (NO) and arginine levels in patients with acute attack, stable and cor pulmonale Chronic Obstuctive Pulmonary disease (COPD).
📊
Key Findings & Data:ADMA and arginine levels were measured by high performance liquid chromatoghraphy with fluorecence detection.
💡
Conclusion & Impact:ADMA may therefore represent a novel therapeutic target for the treatment and prevention of pulmonary hypertension and cor pulmonale in COPD patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The aim of our study was to determine serum asymmetric dimethylarginine (ADMA), nitric oxide (NO) and arginine levels in patients with acute attack, stable and cor pulmonale Chronic Obstuctive Pulmonary disease (COPD). Twenty five acute attack of COPD, twenty five stable of COPD, twenty five cor pulmonale subjects partipicated in this study. To be selected patients had to have no other diseases. The control group was formed by twenty five appearentely healthy people. ADMA and arginine levels were measured by high performance liquid chromatoghraphy with fluorecence detection. Serum nitrite/nitrate concentrations were determined using a commercial colorimetric assay. Patients of acute (p<0.01), stable (p<0.05) and cor pulmonale (p<0.001) of COPD had statistically significant higher values of ADMA compared to control group. There was no difference between stable, attack and control groups for arginine values. Cor pulmonale group had statistically significant lower values arginine compared to control (p<0.05) and attack groups (p<0.01). Our study shows that ADMA level is increased in the acute attack, stable and cor pulmonale of COPD patients. ADMA may play an important role in the progression of pulmonary hypertension in COPD patients. ADMA may therefore represent a novel therapeutic target for the treatment and prevention of pulmonary hypertension and cor pulmonale in COPD patients.

Özet

Bu çalışmada atak, stabil ve kor pulmonale grubu kronik obstrüktif akciğer hastalığı (KOAH) olanlarda asimetrik dimetilarjinin (ADMA), nitrik oksit (NO) ve arjinin düzeylerindeki değişiklikleri belirlemeyi amaçladık. Çalışmamıza 25 akut atak KOAH, 25 stabil KOAH, 25 kor pulmonale hastası dahil edildi. Hastaların KOAH ve kor pulmonale dışında ek bir hastalığı yoktu. Kontrol grubu 25 sağlıklı kişiden oluşturuldu. ADMA ve Arjinin düzeyleri yüksek basınçlı likit kromatografi yöntemiyle floresans dedektörde ölçüldü. Serum nitrit/nitrat konsantrasyonları kolorimetrik metotla ölçüldü. Akut atak,(p<0.01) stabil (p<0.05) ve kor pulmonale (p<0.001) grubu KOAH hastalarında ADMA seviyeleri kontrol grubundan istatistiksel olarak anlamlı yüksek bulundu. Serum arjinin düzeylerinde stabil, atak ve kontrol grupları arasında anlamlı bir değişiklik gözlenmedi. Serum arjinin düzeyleri kor pulmonale grubunda kontrol (p<0.05) ve atak grubuna (p<0.01) oranla istatistiksel olarak anlamlı düşük bulundu. Bizim çalışmamız ADMA seviyelerinin atak, stabil ve kor pulmonale KOAH hastalarında arttığını göstermiştir. Sonuçlarımız artmış ADMA oranının KOAH temelinde gelişen pulmoner hipertansiyonun gelişiminde önemli rolü olabileceğini göstermektedir. Bu hastalarda gelişen pulmoner hipertansiyon ve kor pulmonalenin önlenmesi ve tedavisinde ADMA önemli bir hedef olabilir.

🔖

Cite This Article

ERDEM, S. S., KANAT, F., ÜNLÜ, A. (2010). Investigation of ADMA, arginine and NO levels of patients with acute attack, stable COPD and cor pulmonale. Selçuk Tıp Dergisi, Cilt: 26 - Sayı: 1, 9–13. https://ajindex.com/articles/319283

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Kocabaş A. Kronik Obstrüktif Akciğer Hastalığı. Umut S, Erdinç E (Editörler). Turgut yayıncılık; 2000;1-24
  2. O’Byrne PM, Postma DS. The Many Faces of Airway Inflammation. Asthma and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 1999; 159: 41–66
  3. National Heart, Lung and Blood Instutute. Morbidity and mortality: chartbook cardiovascular, lung and blood diseases. Bethesda, MD: US Departement, of health and Human Services, Public Health Services,: National Instutute of Health: 2003
  4. Numanoğlu N. Solunum Sistemi ve Hastalıkları, Antıp Yayınları 2001; 436- 41
  5. Marletta MA. Nitric oxide synthase: aspects, concerning structure and catalysis. Cell 1994;78:927-30
  6. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992; 26: 1898-902
  7. Naseem KM. The Role of Nitric Oxide İn Cardiovascular Disease Molecular Aspects of Medicine 2005; 26:33-65
  8. Clarke S. Protein methylation. Curr Opin Cell Biol 1993;5:977–83
  9. McBride AE, Silver PA. State of the Arg: protein methylation at arginine comes of age. Cell 2001;106:5–8
  10. Krause CD, Yang ZH, Kim YS, et al. Protein arginine methyltransferases: Evolution and assessment of their pharmacological and therapeutic potential. Pharmacol Ther 2006
  11. Vallance P, Leiper J. Cardiovascular Biology of the Asymmetric Dimethylarginine: Dimethylarginine Dimethylaminohydrolase Pathway. Arterioscler Thromb Vasc Biol 2004;24:1023-30
  12. Millat LJ, Whitley J, Leiper JM, et al. Evidence for Dysregulation of Dimethylarginine Dimethylaminohydrolase I in Chronic Hypoxia-Ýnduced Pulmonary Hypertension. Circulation 2003;108:1493-8
  13. Chen BM, Xia LW, Zhao RQ. Determination of NG, NG dimethylarginine in human plasma by high performance liquit chromatography. J Chromatogr B 1997; 692: 467-71
  14. Pullamsetti S, Kiss L, Ghofrani HA, et al. Increased levels and reduced catabolism asymmetric dimethylarginines in pulmonary hypertension. The FASEB Journal 2005;19: 1175-7
  15. Gorenflo M, Zheng C, Werle E, et al. Plasma levels of asymmetric dimethyl- L-Arginine in Patients with Congenital Heart Disease and pulmonary hypertension. Pharmacology 2001;37:489-92
  16. Arrigoni FI, Vallance P, Haworth SG, Leiper JM. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation 2003;107;1195-201
  17. Anemon A, Backman V, Snygg J, et al. Accumulation of an endogenous inhib